Management of immune-related cutaneous adverse events with dupilumab

Immune checkpoint inhibitors (ICI) target the PD-1/PD-L1 and CTLA-4 pathways and allows the immune system to deliver antitumor effects. However, it is also associated with well-documented immune-related cutaneous adverse events (ircAEs), affecting up to 70–90% of patients on ICI. In this study, we d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Alyce Mei-Shiuan, Gu, Stephanie, Stoll, Joseph, Moy, Andrea P, Dusza, Stephen W, Gordon, Allison, Haliasos, Elena C, Janjigian, Yelena, Kraehenbuehl, Lukas, Quigley, Elizabeth A, Chapman, Paul, Lacouture, Mario E, Markova, Alina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255229/
https://www.ncbi.nlm.nih.gov/pubmed/37270183
http://dx.doi.org/10.1136/jitc-2023-007324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255229/
https://www.ncbi.nlm.nih.gov/pubmed/37270183
http://dx.doi.org/10.1136/jitc-2023-007324

Ejemplares similares